{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:54:42Z","timestamp":1793361282917,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10067-022-06329-2","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T01:02:27Z","timestamp":1660525347000},"page":"3707-3714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-3691","authenticated-orcid":false,"given":"Arne","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-6501","authenticated-orcid":false,"given":"Magdolna Szilvia","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6154-4322","authenticated-orcid":false,"given":"Anna","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5805-806X","authenticated-orcid":false,"given":"Axel","family":"Nigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-8099","authenticated-orcid":false,"given":"Martin","family":"Feuchtenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"issue":"27","key":"6329_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KAs, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group CCT (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383(27):2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"issue":"5","key":"6329_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, Group CS (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"6329_CR3","doi-asserted-by":"crossref","unstructured":"Sood AM, Murthy V, Gonzalez, E. (2021) Efficacy of SARS-CoV-2 vaccine in patients with rheumatic diseases: a systematic review and meta-analysis. In: ACR convergence 2021. All Virtual","DOI":"10.1097\/RHU.0000000000001871"},{"issue":"10","key":"6329_CR4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, Zisapel M, Elalouf O, Kaufman I, Meidan R, Broyde A, Polachek A, Wollman J, Litinsky I, Meridor K, Nochomovitz H, Silberman A, Rosenberg D, Feld J, Haddad A, Gazzit T, Elias M, Higazi N, Kharouf F, Shefer G, Sharon O, Pel S, Nevo S, Elkayam O (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80(10):1330\u20131338. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220647","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"6329_CR5","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, van Dam KPJ, Stalman EW, Vogelzang EH, Cristianawati O, Keijzer S, Vidarsson G, Voskuyl AE, Wieske L, Eftimov F, van Vollenhoven R, Kuijpers TW, van Ham SM, Tas SW, Killestein J, Boers M, Nurmohamed MT, Rispens T, Wolbink G (2021) Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol 3(11):e778\u2013e788. https:\/\/doi.org\/10.1016\/S2665-9913(21)00222-8","journal-title":"Lancet Rheumatol"},{"key":"6329_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.12.006","author":"NG Manolache","year":"2021","unstructured":"Manolache NG, Ursachi V, Scohy A, Desmet C, Yombi JC, Nzeusseu Toukap A, Stoenoiu MS (2021) Attenuated anti-SARS-CoV-2 antibody response to vaccination in patients with rheumatic diseases. J Infect. https:\/\/doi.org\/10.1016\/j.jinf.2021.12.006","journal-title":"J Infect"},{"issue":"10","key":"6329_CR7","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","volume":"80","author":"D Simon","year":"2021","unstructured":"Simon D, Tascilar K, Fagni F, Kronke G, Kleyer A, Meder C, Atreya R, Leppkes M, Kremer AE, Ramming A, Pachowsky ML, Schuch F, Ronneberger M, Kleinert S, Hueber AJ, Manger K, Manger B, Berking C, Sticherling M, Neurath MF, Schett G (2021) SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis 80(10):1312\u20131316. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220461","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"6329_CR8","first-page":"L01","volume":"73","author":"C Raptis","year":"2021","unstructured":"Raptis C, Andrey D, Berger C, Finckh A, Lescuyer P, Ciurea A, Maletic T, Polysopoulos C, Riek M, Scherer A, Lauper K, Moeller B, Safford J, Schweizer S, von Loga I, Vuilleumier N, Rubbert-Roth A (2021) Immunogenicity of mRNA COVID-19 vaccines at 4 and 12 weeks post full vaccination in patients with inflammatory rheumatic diseases [abstract]. Arthritis Rheumatol. 73(suppl 10):L01","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"6329_CR9","doi-asserted-by":"publisher","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","volume":"21","author":"A Jena","year":"2022","unstructured":"Jena A, Mishra S, Deepak P, Kumar MP, Sharma A, Patel YI, Kennedy NA, Kim AHJ, Sharma V, Sebastian S (2022) Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev 21(1):102927. https:\/\/doi.org\/10.1016\/j.autrev.2021.102927","journal-title":"Autoimmun Rev"},{"key":"6329_CR10","doi-asserted-by":"publisher","unstructured":"Feuchtenberger M, Kovacs MS, Eder A, Nigg A, Sch\u00e4fer A (2022) Methotrexate significantly reduces the humoral vaccination response against SARS-CoV-2 in older but not younger patients with rheumatoid arthritis. Int J Rheumatol 42.\u00a0https:\/\/doi.org\/10.1007\/s00296-022-05123-2","DOI":"10.1007\/s00296-022-05123-2"},{"issue":"6","key":"6329_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"6329_CR12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211331","author":"LC Coates","year":"2022","unstructured":"Coates LC, Corp N, van der Windt DA, O\u2019Sullivan D, Soriano ER, Kavanaugh A (2022) GRAPPA treatment recommendations: 2021 update. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.211331","journal-title":"J Rheumatol"},{"issue":"4","key":"6329_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A (2022) Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol 18(4):205\u2013216. https:\/\/doi.org\/10.1038\/s41584-022-00761-z","journal-title":"Nat Rev Rheumatol"},{"key":"6329_CR14","doi-asserted-by":"crossref","unstructured":"Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, Calabrese C, Gravallese EM, Harpaz R, Kroger A, Sadun RE, Turner AS, Williams EA, Mikuls TR (2022) American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5. Available from: https:\/\/www.rheumatology.org\/Portals\/0\/Files\/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf [Accessed 11 July 2022]","DOI":"10.1002\/art.42372"},{"key":"6329_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222006","author":"RBM Landewe","year":"2022","unstructured":"Landewe RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GR et al (2022) EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6329_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/annrheumdis-2021-221366","volume":"81","author":"A Alunno","year":"2022","unstructured":"Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Giacomelli R, Hermine O, Isaacs JD, Kone-Paut I, Magro-Checa C, McInnes IB, Meroni PL, Quartuccio L, Ramanan AV, Ramos-Casals M, Rodriguez Carrio J, Schulze-Koops H, Stamm TA, Tas SW, Terrier B, McGonagle DG, Mariette X (2022) 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Ann Rheum Dis 81(1):34\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221366","journal-title":"Ann Rheum Dis"},{"key":"6329_CR17","unstructured":"(2001) ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med 47(3):199\u2013203"},{"key":"6329_CR18","unstructured":"ICH (2016) Guideline for good clinical practice E6 (R2). ICH Harmonised Tripartite Guideline. Version of December 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf. Accessed 18 Sep, 2020"},{"key":"6329_CR19","unstructured":"SPSS (2008) SPSS for windows release 17.0. In Armonk, NY: IBM; 2008"},{"issue":"10","key":"6329_CR20","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","volume":"80","author":"UM Geisen","year":"2021","unstructured":"Geisen UM, Berner DK, Tran F, Sumbul M, Vullriede L, Ciripoi M, Reid HM, Schaffarzyk A, Longardt AC, Franzenburg J, Hoff P, Schirmer JH, Zeuner R, Friedrichs A, Steinbach A, Knies C, Markewitz RD, Morrison PJ, Gerdes S, Schreiber S, Hoyer BF (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80(10):1306\u20131311. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220272","journal-title":"Ann Rheum Dis"},{"key":"6329_CR21","doi-asserted-by":"publisher","first-page":"607725","DOI":"10.3389\/fmed.2020.607725","volume":"7","author":"RA Moura","year":"2020","unstructured":"Moura RA, Fonseca JE (2020) JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis. Front Med (Lausanne) 7:607725. https:\/\/doi.org\/10.3389\/fmed.2020.607725","journal-title":"Front Med (Lausanne)"},{"key":"6329_CR22","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","volume":"9","author":"S Kubo","year":"2018","unstructured":"Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S, Ishii A, Yamagata K, Nakano K, Tanaka Y (2018) Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol 9:1510. https:\/\/doi.org\/10.3389\/fimmu.2018.01510","journal-title":"Front Immunol"},{"issue":"12","key":"6329_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","volume":"5","author":"K Yamaoka","year":"2004","unstructured":"Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O\u2019Shea JJ (2004) The Janus kinases (Jaks). Genome Biol 5(12):253. https:\/\/doi.org\/10.1186\/gb-2004-5-12-253","journal-title":"Genome Biol"},{"key":"6329_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72 Suppl 2","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72 Suppl 2:111\u2013115. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202576","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6329_CR25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd (2016) The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 75(4):687\u2013695. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207191","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6329_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-019-1883-1","volume":"21","author":"KL Winthrop","year":"2019","unstructured":"Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE (2019) Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. Arthritis Res Ther 21(1):102. https:\/\/doi.org\/10.1186\/s13075-019-1883-1","journal-title":"Arthritis Res Ther"},{"key":"6329_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab879","author":"L Iancovici","year":"2021","unstructured":"Iancovici L, Khateeb D, Harel O, Peri R, Slobodin G, Hazan Y, Melamed D, Kessel A, Bar-On Y (2021) Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab879","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"6329_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","volume":"24","author":"RJ Riese","year":"2010","unstructured":"Riese RJ, Krishnaswami S, Kremer J (2010) Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 24(4):513\u2013526. https:\/\/doi.org\/10.1016\/j.berh.2010.02.003","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"6329_CR29","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","volume":"44","author":"LA O\u2019Sullivan","year":"2007","unstructured":"O\u2019Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC (2007) Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 44(10):2497\u20132506. https:\/\/doi.org\/10.1016\/j.molimm.2006.11.025","journal-title":"Mol Immunol"},{"issue":"5","key":"6329_CR30","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","volume":"178","author":"PJ Murray","year":"2007","unstructured":"Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178(5):2623\u20132629. https:\/\/doi.org\/10.4049\/jimmunol.178.5.2623","journal-title":"J Immunol"},{"issue":"10","key":"6329_CR31","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","volume":"80","author":"MA Friedman","year":"2021","unstructured":"Friedman MA, Curtis JR, Winthrop KL (2021) Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 80(10):1255\u20131265. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221244","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"6329_CR32","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/M21-1757","volume":"174","author":"P Deepak","year":"2021","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, Liu Z, McMorrow LE, Paez D, Pawar N, Perantie DC, Schriefer RE, Sides SE, Thapa M, Gergely M, Abushamma S, Akuse S, Klebert M, Mitchell L, Nix D, Graf J, Taylor KE, Chahin S, Ciorba MA, Katz P, Matloubian M, O\u2019Halloran JA, Presti RM, Wu GF, Whelan SPJ, Buchser WJ, Gensler LS, Nakamura MC, Ellebedy AH, Kim AHJ (2021) Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Intern Med 174(11):1572\u20131585. https:\/\/doi.org\/10.7326\/M21-1757","journal-title":"Ann Intern Med"},{"issue":"2","key":"6329_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","volume":"77","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Lebwohl M, Cohen AD, Weinberg JM, Tyring SK, Rottinghaus ST, Gupta P, Ito K, Tan H, Kaur M, Egeberg A, Mallbris L, Valdez H (2017) Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol 77(2):302\u2013309. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.023","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"6329_CR34","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/art.41805","volume":"73","author":"JR Curtis","year":"2021","unstructured":"Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Gravallese EM, Bass AR, Calabrese C, Harpaz R, Kroger A, Sadun RE, Turner AS, Williams EA, Mikuls TR (2021) Reply. Arthritis. Rheumatol 73(9):1769\u20131770. https:\/\/doi.org\/10.1002\/art.41805","journal-title":"Rheumatol"},{"key":"6329_CR35","doi-asserted-by":"publisher","unstructured":"Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpizar-Rodriguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, El Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larche M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA (2021) Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 7(3). https:\/\/doi.org\/10.1136\/rmdopen-2021-001814","DOI":"10.1136\/rmdopen-2021-001814"},{"key":"6329_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221575","author":"FPB Kroon","year":"2021","unstructured":"Kroon FPB, Najm A, Alunno A, Schoones JW, Landewe RBM, Machado PM, Navarro-Compan V (2021) Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221575","journal-title":"Ann Rheum Dis"},{"key":"6329_CR37","doi-asserted-by":"publisher","DOI":"10.2174\/2589977514666220304203816","author":"A Saeedi-Boroujeni","year":"2022","unstructured":"Saeedi-Boroujeni A, Asadi-Samani M (2022) JAK inhibitors as a barrier to the destructive cytokine storm in COVID-19. Curr Drug Res Rev. https:\/\/doi.org\/10.2174\/2589977514666220304203816","journal-title":"Curr Drug Res Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06329-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T13:09:42Z","timestamp":1668172182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06329-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6329"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06329-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"10 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent for study participation and publication of the scientific data obtained. This study was approved by the ethics committee of the University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany. The process of organising and conducting the study followed the principles of \u201cGood Clinical Practice\u201d [, ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Sch\u00e4fer reports personal fees from Amgen, AstraZeneca, and Novo Nordisk Pharma GmbH outside of the submitted work. Dr. Kovacs has nothing to disclose. Dr. Eder has nothing to disclose. Dr. Nigg has nothing to disclose. Dr. Feuchtenberger reports personal fees from AbbVie, Novartis, Roche, and UCB outside of the submitted work. All authors disclosed financial or nonfinancial interests that are directly or indirectly related to the work submitted for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}